_edited.png)
Our Technology
At Therapain5, we harness the power of innovative drug formulation to tackle one of the most challenging health issues of our time: chronic pain. Our pioneering product, GBM-5, is a testament to our commitment to science, safety, and efficacy.
GBM-5: A Revolutionary Approach GBM-5 is not just another pain medication. It’s a unique formulation that combines five well-established drugs in precise ratios to act on different pain pathways simultaneously. This multi-faceted approach addresses both pain and inflammation, providing a comprehensive solution for patients who have not found relief with traditional treatments.
Patent Portfolio
Therapain5 prides itself on a robust intellectual property portfolio that safeguards our innovative pharmaceutical solutions. Here is an overview of our key patents:
_edited_edited.png)
US Patent
Our flagship product, GBM-5, is protected under US Patent No. 10,350,203B2, titled "Multidrug Infusion for Pain Control." This patent, valid until 2035, covers the unique formulation, its various administration routes, and all its potential uses.
International Patents
In addition to our US patent, we have filed patents in multiple jurisdictions to ensure global protection. These include Canada, Europe, Australia, China, Japan, South Korea, Hong Kong, and Taiwan. These patents are currently pending.
Provisional Patents
We have filed three provisional patents to further protect our innovations:
-
Intranasal Anti-Inflammatory Multidrug Infusion (P4956US03): Filed on March 14, 2022.
-
Anti-Inflammatory Multidrug Infusion for Animals (P5292US01): Filed on November 17, 2021.
-
Topical Analgesic Formulation (P5017US02): Filed on March 3, 2022.